The role of LAT protein condensation phase transitions in T cell signaling

LAT 蛋白缩合相变在 T 细胞信号传导中的作用

基本信息

  • 批准号:
    10428140
  • 负责人:
  • 金额:
    $ 46.7万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2011
  • 资助国家:
    美国
  • 起止时间:
    2011-07-15 至 2027-04-30
  • 项目状态:
    未结题

项目摘要

ABSTRACT - Project 3 A healthy immune system depends on T cells’ abilities to detect foreign agonist pMHC molecules, at near single molecule levels, among vast numbers of sometimes very similar self-antigens. While the T cell’s fine discrimination capabilities are experimentally well established, understanding how the molecular machinery of the TCR signaling system achieves this is far from transparent. Fundamental issues of noise, variation, and signal fidelity present serious challenges—both for understanding how the T cell works as well as for development of therapeutic strategies utilizing T cells. Recently, a class of phenomena known as protein condensation phase transitions have begun to emerge in biology. Originally identified in the context of nuclear organization and gene expression, a distinct two-dimensional protein condensation on the cell membrane has now been discovered in the T cell receptor (TCR) signaling system involving the scaffold protein LAT. While the role of LAT as a scaffold for the clustering of downstream signaling molecules in T cells has long been recognized, experimental realization that this structure can form through distinct types of phase transition processes is more recent. Protein condensation phase transitions can exhibit a wide range of properties that differ substantially from more linear molecular clustering processes, and thus offer a variety of different ways to regulate the functional output of molecular signaling systems. Project 3 addresses the overarching hypothesis that unique properties of the LAT protein condensation phase transition enable the remarkable sensitivity and selectivity T cells exhibit during antigen recognition. We propose a series of investigations to test aspects of this hypothesis that combine highly quantitative experiments in reconstituted molecular systems with precision single-molecule live cell experiments in primary T cells. We have preliminary data indicating that LAT condensation in live T cells is controlled by an unusual type of kinetic phase transition and that specific molecular features of proximal TCR signaling are tuned to take advantage of this. Confirmation and elucidation of this discovery will form the foundation of our more detailed investigation into the role of the phase transition in TCR signaling. While Projects 1 and 2 focus on proximal signaling feedback mechanisms leading up to LAT phosphorylation and condensate nucleation, and Project 4 examines signaling downstream from the LAT condensate, Project 3 emphasizes experimental and computational characterization of the LAT condensation phase transition itself and measurements of how its properties modulate downstream signal propagation through the following specific aims: 1. Define the factors controlling initiation of LAT condensation in T cells; 2. Engineer non-condensing LAT and LAT-like systems; 3. Define how LAT condensates control downstream signaling to Ras and Ca2+ pathways. Insights originating from this work will likely resolve some conceptual mysteries on mechanistic function of the T cell receptor signaling pathway and highlight alternative angles to engineer and manipulate T cells for therapeutic benefit.
摘要-项目3 一个健康的免疫系统依赖于T细胞检测外源激动剂pMHC分子的能力, 分子水平,在大量的有时非常相似的自身抗原中。T细胞没事的时候 辨别能力是实验上建立良好的,了解如何分子机制, TCR信号系统实现这一点远非透明。噪声、变化和 信号保真度提出了严重的挑战-无论是理解T细胞如何工作, 开发利用T细胞的治疗策略。最近,一类被称为蛋白质的现象 凝结相变已经开始出现在生物学中。最初是在核问题的背景下确定的, 组织和基因表达,一个独特的二维蛋白质凝聚在细胞膜上, 现在在涉及支架蛋白LAT的T细胞受体(TCR)信号传导系统中发现。而 LAT作为T细胞中下游信号分子聚集的支架的作用长期以来一直是 公认的,实验性的认识,这种结构可以形成通过不同类型的相变 过程是最近的。蛋白质缩合相变可以表现出广泛的性质, 基本上不同于更线性的分子聚类过程,因此提供了各种不同的方法来 调节分子信号系统的功能输出。项目3解决了 假设LAT蛋白质缩合相变独特性质使得 T细胞在抗原识别过程中表现出显著的敏感性和选择性。我们提出了一系列 为了检验这一假设的各个方面,联合收割机结合了重组的高定量实验, 分子系统与原代T细胞中的精确单分子活细胞实验。我们有初步的 数据表明,活T细胞中的LAT凝聚是由一种不寻常的动力学相变类型控制的, 并且近端TCR信号传导的特定分子特征被调整以利用这一点。确认 这一发现的阐明将成为我们对这一发现的作用进行更详细研究的基础。 TCR信号传导中的相变。而项目1和项目2则侧重于近端信号反馈机制 导致LAT磷酸化和冷凝物成核,项目4检查下游信号传导 从LAT冷凝物,项目3强调LAT的实验和计算表征 冷凝相变本身及其性质如何调制下游信号的测量 通过以下具体目标进行宣传:1.定义控制LAT启动的因素 T细胞中的凝聚; 2.工程师非冷凝LAT和LAT类系统; 3.定义LAT如何 缩合物控制Ras和Ca 2+途径的下游信号传导。源自这项工作的见解 将可能解决一些概念上的奥秘,机械功能的T细胞受体信号通路 并强调了工程和操纵T细胞以获得治疗益处的替代角度。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

JAY T. GROVES其他文献

JAY T. GROVES的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('JAY T. GROVES', 18)}}的其他基金

ECM geometrical and mechanical properties modulate RTK signaling
ECM 几何和机械特性调制 RTK 信号
  • 批准号:
    9763512
  • 财政年份:
    2015
  • 资助金额:
    $ 46.7万
  • 项目类别:
The role of LAT protein condensation phase transitions in T cell signaling
LAT 蛋白缩合相变在 T 细胞信号传导中的作用
  • 批准号:
    10615830
  • 财政年份:
    2011
  • 资助金额:
    $ 46.7万
  • 项目类别:
Fundamental Mechano-Chemical Mechanisms of Signaling in Cancer
癌症信号转导的基本机械化学机制
  • 批准号:
    7814885
  • 财政年份:
    2009
  • 资助金额:
    $ 46.7万
  • 项目类别:
Quantitative Studies of the Immunological Synapse
免疫突触的定量研究
  • 批准号:
    6710136
  • 财政年份:
    2002
  • 资助金额:
    $ 46.7万
  • 项目类别:
Quantitative Studies of the Immunological Synapse
免疫突触的定量研究
  • 批准号:
    6620904
  • 财政年份:
    2002
  • 资助金额:
    $ 46.7万
  • 项目类别:
Quantitative Studies of the Immunological Synapse
免疫突触的定量研究
  • 批准号:
    6422943
  • 财政年份:
    2002
  • 资助金额:
    $ 46.7万
  • 项目类别:
Quantitative Studies of the Immunological Synapse
免疫突触的定量研究
  • 批准号:
    7068722
  • 财政年份:
    2002
  • 资助金额:
    $ 46.7万
  • 项目类别:
Quantitative Studies of the Immunological Synapse
免疫突触的定量研究
  • 批准号:
    6861864
  • 财政年份:
    2002
  • 资助金额:
    $ 46.7万
  • 项目类别:
Fundamental Mechano-Chemical Mechanisms of Signaling in Cancer
癌症信号转导的基本机械化学机制
  • 批准号:
    8182469
  • 财政年份:
  • 资助金额:
    $ 46.7万
  • 项目类别:
Fundamental Mechano-Chemical Mechanisms of Signaling in Cancer
癌症信号转导的基本机械化学机制
  • 批准号:
    8381408
  • 财政年份:
  • 资助金额:
    $ 46.7万
  • 项目类别:

相似国自然基金

Agonist-GPR119-Gs复合物的结构生物学研究
  • 批准号:
    32000851
  • 批准年份:
    2020
  • 资助金额:
    24.0 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
  • 批准号:
    24K12256
  • 财政年份:
    2024
  • 资助金额:
    $ 46.7万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
  • 批准号:
    24K19176
  • 财政年份:
    2024
  • 资助金额:
    $ 46.7万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
  • 批准号:
    10578068
  • 财政年份:
    2023
  • 资助金额:
    $ 46.7万
  • 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
  • 批准号:
    10933287
  • 财政年份:
    2023
  • 资助金额:
    $ 46.7万
  • 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
  • 批准号:
    10650593
  • 财政年份:
    2023
  • 资助金额:
    $ 46.7万
  • 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
  • 批准号:
    10649275
  • 财政年份:
    2023
  • 资助金额:
    $ 46.7万
  • 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
  • 批准号:
    10734158
  • 财政年份:
    2023
  • 资助金额:
    $ 46.7万
  • 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
  • 批准号:
    10784209
  • 财政年份:
    2023
  • 资助金额:
    $ 46.7万
  • 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
  • 批准号:
    10580259
  • 财政年份:
    2023
  • 资助金额:
    $ 46.7万
  • 项目类别:
Identification and characterization of a plant growth promoter from wild plants: is this a novel plant hormone agonist?
野生植物中植物生长促进剂的鉴定和表征:这是一种新型植物激素激动剂吗?
  • 批准号:
    23K05057
  • 财政年份:
    2023
  • 资助金额:
    $ 46.7万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了